Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + pegylated interferon alfa-2a
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This combination therapy consists of entecavir, a potent guanosine nucleoside analogue, and pegylated interferon alfa-2a, a long-acting interferon formulation. It is primarily utilized in clinical research, such as the Phase 4 trial conducted by Beijing Friendship Hospital, to evaluate the regression of liver fibrosis in patients with chronic hepatitis B (CHB). Entecavir functions by inhibiting the hepatitis B virus (HBV) polymerase, which blocks viral DNA synthesis at multiple stages. Pegylated interferon alfa-2a is a cytokine that binds to the Type I interferon receptor (IFNAR), triggering intracellular signaling pathways that enhance the host's innate and adaptive immune responses against HBV. Together, the combination aims to achieve both profound viral suppression and immune-mediated clearance of infected hepatocytes, potentially leading to the reversal of histological liver damage and fibrosis.
- Brand names
- BaracludePegasys
- Other names
- ETV + Peg-IFN-alpha-2aPeg-IFN + ETVPegylated interferon alpha-2a plus entecavir
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on entecavir + pegylated interferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + pegylated interferon alfa-2a.